Antoine Hollebecque

46PUBLICATIONS
332CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Sep 23, 2026
Gustave Roussy Immune (GRIm) score validation in patients treated with Bispecific CD3 T-cell engagers in phase I clinical trials.

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|Jul 01, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

|May 18, 2026
Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

|Apr 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.

|Feb 03, 2026
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé

Pageof 8

Frequent Collaborators

10 joint publications

Damien Vasseur

8 joint publications

Luc Friboulet

7 joint publications

Yohann Loriot

6 joint publications

Antoine Italiano